MARKET

AVDL

AVDL

Avadel
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.47
+0.16
+2.19%
Closed 13:00 11/27 EST
OPEN
7.30
PREV CLOSE
7.31
HIGH
7.55
LOW
7.30
VOLUME
258.54K
TURNOVER
--
52 WEEK HIGH
13.49
52 WEEK LOW
4.000
MARKET CAP
434.91M
P/E (TTM)
-98.2895
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Avadel Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Update on FT218 Development Program
* NDA for once-nightly FT218 is on track for FDA submission by end of December 2020 * New market assessment data identifies a significant potential market expansion opportunity for once-nightly FT218 beyond existing twice-nightly sodium oxybate patients * Management to host a conference call today at 8:30 a.m. ET DUBLIN, Ireland, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced its financial results for the third quarter ended September 30, 2020 and provided a business update.“Over the past several months, the Avadel clinical and regulatory teams have made substantial progress in advancing FT218 toward its anticipated FDA approval for the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy. The Company remains on track to submit the filing to the FDA by the end of December. We are pleased with the progress we have made despite the challenges of a global pandemic and look forward to updating our shareholders on this upcoming regulatory milestone for the FT218 program,” said Greg Divis, Chief Executive Officer of Avadel.“We recently gained even greater insight into this evolving therapeutic area including the significant and growing opportunity for FT218. Specifically, we completed a comprehensive market assessment, which provided current and critical prescriber and patient insights. A key finding is that six out of ten sodium oxybate-eligible patients are not going on therapy today, with twice-nightly dosing being the primary reason cited. This finding suggests there could be a significantly larger potential sodium oxybate-eligible market beyond those currently being treated with twice-nightly therapy. These insights, coupled with patient discontinuation rates of nearly 50% within the first 12 months of initiating twice-nightly therapy, underscore the unmet patient need and opportunity once-nightly FT218 may have in addition to the nearly $1.8 billion1 twice-nightly sodium oxybate market. Based on our extensive research, we believe once-nightly FT218 has the potential, if approved, to offer a meaningful treatment option for patients switching from twice-nightly sodium oxybate, as well as those patients who previously refused or discontinued twice-nightly therapy,” concluded Mr. Divis.Third quarter and recent company highlights• FT218 NDA is on track and expected to be filed with the FDA by the end of December. • Completed a new comprehensive market assessment that included a review of over five years of twice-nightly sodium oxybate utilization and interviews with over 500 critical stakeholders. Key findings from the market assessment include: * Insights from over 150 sodium oxybate prescribing physicians show that 60% of sodium oxybate-eligible patients are not receiving sodium oxybate treatment today, with the primary reason being twice-nightly dosing-related challenges. * In a survey of current sodium oxybate-treated patients, once-nightly dosing ranked as the most important driver of their treatment preference, placing it higher in importance than efficacy and side effect profile. * Analysis of longitudinal patient claims analysis demonstrates nearly 50% of all newly treated twice-nightly sodium oxybate patients discontinued their treatment within 12 months of initiation, including about half of that group discontinuing within the first 30 days.• Supported a recently published article in the peer-reviewed journal Sleep Medicine highlighting the lack of evidence linking the sodium content of sodium oxybate with increased cardiovascular risk in patients with narcolepsy. (https://doi.org/10.1016/j.sleep.2020.09.017) • Additional subgroup analysis of the REST-ON study demonstrated comparable, robust results for FT218 in narcolepsy patients both with and without cataplexy as well as those on concomitant wake-promoting agents compared to those not on wake-promoting agents. In addition, results of responder analyses for the Maintenance of Wakefulness Test and mean weekly cataplexy attacks further supported the potential clinical benefits of FT218. • Continued progress of the RESTORE trial, an open-label extension/switch study of FT218 as a potential treatment for excessive daytime sleepiness and cataplexy in patients with narcolepsy. * 29 patients have been enrolled and initiated treatment or are pending treatment initiation. * The majority of these patients switched from twice-nightly sodium oxybate, many of which also completed the REST-ON study, and nearly all are on the same or lower stable dose of FT218 compared to their prior twice-nightly treatment.• U.S. Patent & Trademark Office issued the second U.S. patent covering once-nightly gamma- hydroxybutyrate formulations, including FT218, with an expiration date of mid-2037. In addition, Avadel has several patent applications pending at the USPTO, which the Company expects to result in additional issued patents in the future. Overview of Third Quarter ResultsAs a result of the sale of the sterile injectable products to Exela Sterile Medicines LLC, which closed on June 30, 2020, the Company did not report any revenue for the third quarter of 2020, compared to $14.2 million in the third quarter of 2019.R&D expenses were $5.6 million in the third quarter of 2020, compared to $7.5 million in the third quarter of 2019. The decrease on a year-over-year basis was primarily attributed to the completion of the FT218 clinical study during the first quarter of 2020, as well as lower headcount due to the restructuring activities initiated during 2019. SG&A expenses were $8.4 million in the third quarter of 2020, compared to $5.3 million in the third quarter of 2019. The year-over-year increase is primarily the result of higher stock-based compensation, professional fees and market preparation costs related to FT218.Net loss for the third quarter of 2020 was $11.7 million, or ($0.20) per diluted share, compared to a net loss of $8.9 million, or ($0.24) per diluted share, for the same period in 2019. The increase in net loss is primarily the result of the year-over-year decline in revenue due to the sale of the sterile injectable products to Exela Sterile Medicines LLC on June 30, 2020. The decrease in diluted loss per share is due to a higher number of shares outstanding resulting from equity issuances completed during the first half of the year.Cash, cash equivalents and marketable securities were $231.6 million as of September 30, 2020. The Company has convertible debt of $143.8 million due in February 2023.Conference Call: A conference call to discuss these results has been scheduled for Monday, November 9, 2020 at 8:30 a.m. ET. To access the conference call, investors are invited to dial (877) 407-9716 (U.S. and Canada) or (201) 493-6779 (International). The conference ID number is 13712485. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.About FT218 FT218 is an investigational, once-nightly formulation of Micropump™ controlled-release (CR) sodium oxybate. In March of 2020, the Company completed the REST-ON study, a pivotal, double-blind, randomized, placebo-controlled Phase 3 trial, to assess the efficacy and safety of FT218 in the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy. FT218 has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of narcolepsy. The designation was granted on the plausible hypothesis that FT218 may be clinically superior to the twice-nightly formulation of sodium oxybate already approved by the FDA for the same indication. In particular, FT218 may be safer due to ramifications associated with the dosing regimen of the previously approved product.About Avadel Pharmaceuticals plc: Avadel Pharmaceuticals plc (Nasdaq: AVDL) is an emerging biopharmaceutical company. The Company’s primary focus is the development and FDA approval of FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy. For more information, please visit www.avadel.com.Footnote: 1. Annualized Xyrem revenues from the Jazz Pharmaceuticals third quarter and year to date results reported in their press release dated November 2, 2020.Cautionary Disclosure Regarding Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements relate to our future expectations, beliefs, plans, strategies, objectives, results, conditions, financial performance, prospects, or other events. Such forward-looking statements include, but are not limited to, the planned submission of the FT218 NDA to the FDA and commercial launch of FT218, if approved. In some cases, forward-looking statements can be identified by the use of words such as “will,” “may,” “could,” “believe,” “expect,” “look forward,” “on track,” “guidance,” “anticipate,” “estimate,” “project,” “next steps” and similar expressions, and the negatives thereof (if applicable).Our forward-looking statements are based on estimates and assumptions that are made within the bounds of our knowledge of our business and operations and that we consider reasonable. However, our business and operations are subject to significant risks, and, as a result, there can be no assurance that actual results and the results of our business and operations will not differ materially from the results contemplated in such forward-looking statements. Factors that could cause actual results to differ from expectations in our forward-looking statements include the risk that we do not file the NDA for FT218 on a timely basis or at all, the risk that the FDA does accept such NDA, the risk that such NDA is not approved by the FDA or such approval is delayed, the risk that the RESTORE study may be delayed or may not be completed at all, the risk that commercial launch of FT218 (if approved) is delayed, the risk that the potential market performance for FT218 (if approved) may differ materially from projections, and the risk that the impact of the current COVID-19 pandemic on our financial results and results of operations could be greater than we anticipate and the risks and uncertainties described in the “Risk Factors” section of Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019, which we filed with the Securities and Exchange Commission (SEC) on March 16, 2020 and subsequent SEC filings.Forward-looking statements speak only as of the date they are made and are not guarantees of future performance. Accordingly, you should not place undue reliance on forward-looking statements. We do not undertake any obligation to publicly update or revise our forward-looking statements, except as required by law.Contacts: Investor Contacts Tom McHugh Chief Financial Officer Phone: (636) 449-1843 Email: tmchugh@avadel.comTim McCarthy LifeSci Advisors, LLC Phone: (212) 915.2564 Email: tim@lifesciadvisors.comMedia Contact Patrick Bursey LifeSci Communications, LLC Phone: (646) 970-4688 Email: pbursey@lifescicomms.comAVADEL PHARMACEUTICALS PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF (LOSS) INCOME (In thousands, except per share data) (Unaudited)  Three Months Ended September 30, Nine Months Ended September 30,   2020 2019 2020 2019           Product sales $—  $14,229  $22,334  $48,220  Operating expenses:         Cost of products —  2,823  5,742  9,711  Research and development expenses 5,569  7,539  15,156  25,160  Selling, general and administrative expenses 8,423  5,316  23,431  22,520  Intangible asset amortization —  205  406  610  Changes in fair value of contingent consideration (69) 627  3,327  2,384  Gain on sale of Hospital Products —  —  (45,760) —  Restructuring (income) costs (226) 1,866  (43) 4,600  Total operating expense 13,697  18,376  2,259  64,985  Operating (loss) income (13,697) (4,147) 20,075  (16,765) Investment and other income (expense), net 213  781  (906) 2,548  Interest expense (3,259) (3,125) (9,686) (9,293) Loss on deconsolidation of subsidiary —  —  —  (2,840) Other expense - changes in fair value of contingent consideration payable —  (139) (435) (496) (Loss) income before income taxes (16,743) (6,630) 9,048  (26,846) Income tax (benefit) provision (5,040) 2,234  (9,258) 3,641  Net (loss) income $(11,703) $(8,864) $18,306  $(30,487)           Net (loss) income per share - basic $(0.20) $(0.24) $0.36  $(0.82) Net (loss) income per share - diluted (0.20) (0.24) 0.35  (0.82)           Weighted average number of shares outstanding - basic 58,213  37,436  51,206  37,382  Weighted average number of shares outstanding - diluted 58,213  37,436  52,849  37,382  AVADEL PHARMACEUTICALS PLC UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except per share data)  September 30, 2020 December 31, 2019   (unaudited)   ASSETS     Current assets:     Cash and cash equivalents $83,109  $9,774  Marketable securities 148,467  54,384  Accounts receivable —  8,281  Inventories —  3,570  Research and development tax credit receivable 3,058  2,107  Prepaid expenses and other current assets 47,054  4,264  Total current assets 281,688  82,380  Property and equipment, net 373  544  Operating lease right-of-use assets 2,866  3,612  Goodwill 16,836  18,491  Intangible assets, net —  813  Research and development tax credit receivable 3,608  6,322  Other non-current assets 22,264  39,274  Total assets $327,635  $151,436        LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)     Current liabilities:     Current portion of long-term contingent consideration payable $—  $5,554  Current portion of operating lease liability 520  645  Accounts payable 2,660  6,100  Accrued expenses 16,398  19,810  Other current liabilities 3,431  3,875  Total current liabilities 23,009  35,984        Long-term debt 126,520  121,686  Long-term contingent consideration payable, less current portion —  11,773  Long-term operating lease liability 1,968  2,319  Other non-current liabilities 4,938  8,873  Total liabilities 156,435  180,635        Shareholders’ equity (deficit):     Preferred shares, nominal value of $0.01 per share; 50,000 shares authorized; 488 issued and outstanding at September 30, 2020 and none issued and outstanding at December 31, 2019, respectively 5  —  Ordinary shares, nominal value of $0.01 per share; 500,000 shares authorized; 58,243 issued and outstanding at September 30, 2020 and 42,927 issued and 37,520 outstanding at December 31, 2019 582  429  Treasury shares, at cost, 0 and 5,407 shares held at September 30, 2020 and December 31, 2019, respectively —  (49,998) Additional paid-in capital 565,440  434,391  Accumulated deficit (372,909) (391,215) Accumulated other comprehensive loss (21,918) (22,806) Total shareholders’ equity (deficit) 171,200  (29,199) Total liabilities and shareholders’ equity (deficit) $327,635  $151,436  AVADEL PHARMACEUTICALS PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited)  Nine Months Ended September 30,   2020 2019       Cash flows from operating activities:     Net income (loss) $18,306  $(30,487) Adjustments to reconcile net income (loss) to net cash provided by operating activities:     Depreciation and amortization 1,297  1,690  Loss on disposal of property and equipment —  478  Remeasurement of acquisition-related contingent consideration 3,327  2,384  Remeasurement of financing-related contingent consideration 435  496  Amortization of debt discount and debt issuance costs 4,835  4,424  Change in deferred tax and income tax deferred charge (4,582) 1,333  Stock-based compensation expense 1,705  177  Gain on the disposition of the hospital products (45,760) —  Loss on deconsolidation of subsidiary —  1,750  Other adjustments 306  (667) Net changes in assets and liabilities     Accounts receivable 8,281  2,026  Inventories (1,352) 2,465  Prepaid expenses and other current assets 1,759  (1,859) Research and development tax credit receivable 2,036  (749) Accounts payable & other current liabilities (4,051) 259  Accrued expenses (6,625) (2,379) Earn-out payments for contingent consideration in excess of acquisition-date fair value (5,323) (8,640) Royalty payments for contingent consideration payable in excess of original fair value (866) (1,374) Other assets and liabilities (3,337) (1,399) Net cash used in operating activities 29,609  (30,072)       Cash flows from investing activities:     Purchases of property and equipment (33) (29) Proceeds from the disposal of property and equipment —  154  Proceeds from the disposition of the hospital products 17,250  —  Proceeds from sales of marketable securities 30,075  57,242  Purchases of marketable securities (124,254) (23,814) Net cash (used in) provided by investing activities (76,962) 33,553        Cash flows from financing activities:     Proceeds from the February 2020 private placement 60,570  —  Proceeds from the May 2020 public offering 116,924  —  Proceeds from stock option exercises and ESPP 2,006  123  Other financing activities, net —  (109) Net cash provided by financing activities 179,500  14        Effect of foreign currency exchange rate changes on cash and cash equivalents 406  47        Net change in cash and cash equivalents 73,335  3,542  Cash and cash equivalents at January 1, 9,774  9,325  Cash and cash equivalents at September 30, $83,109  $12,867  AVADEL PHARMACEUTICALS PLC UNAUDITED SUPPLEMENTAL INFORMATION (In thousands, except per share data) (Unaudited)  Three Months Ended September 30, Nine Months Ended September 30, Revenues by Product: 2020 2019 2020 2019           Bloxiverz $—  $1,466  $2,201  $6,392  Vazculep —  8,786  10,429  27,669  Akovaz —  4,208  9,545  13,946  Other —  (231) 159  213  Total product sales $—  $14,229  $22,334  $48,220
GlobeNewswire · 11/09 12:00
Avadel Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 9th
DUBLIN, Ireland, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, November 9, 2020, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2020. To access the conference call, investors are invited to dial 877-407-9716 (U.S. and Canada) or 201-493-6779 (international). The conference ID number is 13712485. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.About Avadel Pharmaceuticals plc: Avadel Pharmaceuticals plc (Nasdaq: AVDL) is an emerging biopharmaceutical company. The Company’s primary focus is the development and FDA approval of FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy. For more information, please visit www.avadel.com.Cautionary Disclosure Regarding Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements relate to our future expectations, beliefs, plans, strategies, objectives, results, conditions, financial performance, prospects, or other events. Such forward-looking statements include, but are not limited to, the planned submission of the FT218 NDA to the FDA and commercial launch of FT218, if approved. In some cases, forward-looking statements can be identified by the use of words such as “will,” “may,” “could,” “believe,” “expect,” “look forward,” “on track,” “guidance,” “anticipate,” “estimate,” “project,” “next steps” and similar expressions, and the negatives thereof (if applicable).Our forward-looking statements are based on estimates and assumptions that are made within the bounds of our knowledge of our business and operations and that we consider reasonable. However, our business and operations are subject to significant risks, and, as a result, there can be no assurance that actual results (including, without limitation, the continued advancement and development of FT218 and potential benefits and cost savings from the sale of our sterile injectible products) and the results of our business and operations will not differ materially from the results contemplated in such forward-looking statements. Factors that could cause actual results to differ from expectations in our forward-looking statements include the risk that we do not file the NDA for FT218 on a timely basis or at all, the risk that the FDA does accept such NDA or does not approve FT218, and the risk that the impact of the current COVID-19 pandemic on our financial results and results of operations could be greater than we anticipate and the risks and uncertainties described in the “Risk Factors” section of Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019, which we filed with the Securities and Exchange Commission (SEC) on March 16, 2020 and subsequent SEC filings.Forward-looking statements speak only as of the date they are made and are not guarantees of future performance. Accordingly, you should not place undue reliance on forward-looking statements. We do not undertake any obligation to publicly update or revise our forward-looking statements, except as required by law.Contacts:Investor Contacts Tom McHugh Chief Financial Officer Phone: (636) 449-1843 Email: tmchugh@avadel.com          Tim McCarthy LifeSci Advisors, LLC Phone: (212) 915.2564 Email: tim@lifesciadvisors.comMedia Contact Patrick Bursey LifeSci Communications, LLC Phone: (646) 970-4688 Email: pbursey@lifescicomms.com
GlobeNewswire · 10/26 13:00
Hedge Funds Have Never Been This Bullish On Avadel Pharmaceuticals plc (AVDL)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds’ and successful investors’ positions as of the end of the second quarter. You can find articles about an individual
Insider Monkey · 10/07 14:38
What You Need To Know About Avadel Pharmaceuticals plc's (NASDAQ:AVDL) Investor Composition
If you want to know who really controls Avadel Pharmaceuticals plc (NASDAQ:AVDL), then you'll have to look at the...
Simply Wall St. · 09/30 11:58
AXGT, AVDL, INMD and IMGN among after-hours movers
Gainers: [[JAX]] +4.5%. [[AXGT]] +4.4%. [[HRI]] +3.1%. [[AVDL]] +2.3%. [[AAL]] +1.7%.Losers: [[TATT]] -6.2%. [[FNKO]] -3.5%. [[IMGN]] -3.0%. [[VIVO]] -2.6%. [[INMD]] -1.6%.
Seekingalpha · 09/25 21:43
AGRX, AVDL among pre-market gainers
NTN Buzztime (NTN) +20% on offloading entertainment and advertising assets.Leap Therapeutics (LPTX) +7% on initiating DKN-01+tislelizumab combination mid-stage study in gastric cancer.Agile Therapeutics (AGRX) +7%.Avadel Pharmaceuticals (AVDL) +5%.Aemetis (AMTX) +5%.PolyMet Mining (PLM) +5%.
Seekingalpha · 09/21 12:09
MFA, TCOM, AVDL and TLSA among after-hours movers
Gainers: [[NTN]] +18.6%. [[AVDL]] +13.6%. [[GRIN]] +5.2%. [[PHAS]] +5%. [[MFA]] +5%.Losers: [[ACET]] -10.7%. [[TLSA]] -8.1%. [[TCOM]] -7.1%. [[JW.A]] -5.3%. [[ARAY]] -4.9%.
Seekingalpha · 09/18 21:44
Avadel To Present At Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Sept. 22
DUBLIN, Ireland, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc(NASDAQ:AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate, today announced that its
Benzinga · 09/17 12:26
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AVDL. Analyze the recent business situations of Avadel through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AVDL stock price target is 17.88 with a high estimate of 23.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 124
Institutional Holdings: 43.48M
% Owned: 74.67%
Shares Outstanding: 58.22M
TypeInstitutionsShares
Increased
25
2.29M
New
32
-4.39M
Decreased
19
2.71M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.12%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Non-Executive Chairman/Independent Director
Geoffrey Glass
Chief Executive Officer/Chief Operating Officer/Executive Vice President/Director
Gregory Divis
Chief Financial Officer
Thomas McHugh
Independent Director
Eric Ende
Independent Director
Mark McCamish
Independent Director
Linda Palczuk
Independent Director
Peter Thornton
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AVDL
Avadel Pharmaceuticals plc is a biopharmaceutical company. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Avadel Pharmaceuticals PLC (ADR) stock information, including NASDAQ:AVDL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVDL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVDL stock methods without spending real money on the virtual paper trading platform.